View More View Less
  • 1 Debreceni Egyetem, Általános Orvostudományi Kar, Debrecen, Nagyerdei krt. 98., 4032
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $1,070.00

Absztrakt:

Az irodalmi adatokra, de kis részben saját tapasztalatokra is támaszkodó közlemény összefoglalja a rekombináns aktív FVII (rFVIIa, Novoseven) alkalmazását a standard indikációkban (inhibitoros és gátlótestes haemophilia, prophylaxis, Glanzmann-thrombasthenia). Értékeli a készítmény különlegesen gyors és hatékony, immunológiai és thrombogen tulajdonságok szempontjából is rendkívül előnyös tulajdonságait. Óvatosan értékeli a nemzetközi ajánlásokra támaszkodva alkalmazásának lehetőségeit, szakmai feltételeit, bizonyos életveszélyes vérzésekben is. Orv Hetil. 2017; 158(24): 923–928.

  • 1

    Hedner U. Recombinant activated factor VII: 30 years of research and innovation. Blood Rev. 2015; 29(S1): S4–S8.

  • 2

    Santagostino E, Escobar M, Ozelo M, et al. Recombinant activated factor VII in the treatment of bleeds and for the prevention of surgery-related bleeding in congenital haemophilia with inhibitors. Blood Rev. 2015; 29(S1): S9–S18.

  • 3

    Lassinger CA, Singleton T, Kruse-Jarres R. How I use bypassing therapy for prophylaxis in patients with hemophilia A and inhibitors. Blood 2015; 126: 153–159.

  • 4

    Astermark J, Donfield SM, DiMichele DM, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007; 109: 546–551.

  • 5

    Kavakli K, Makris M, Zulfikar B, et al. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial. Thromb Haemost. 2006; 95: 600–605.

  • 6

    Mathijssen NC, Masereeuw R, Holme PA, et al. Increased volume of distribution for recombinant activated factor VII and longer plasma-derived factor VII half-life may explain their long lasting prophylactic effect. Thromb Res. 2013; 132: 256–262.

  • 7

    Schut AM, Hyseni A, Adelmeijer J, et al. Sustained pro-haemostatic activity of rFVIIa in plasma and platelets in non-bleeding pigs may explain the efficacy of a once-daily prophylaxis in humans. Thromb Haemost. 2014; 112: 304–310.

  • 8

    Poon MC, Di Minno G, d’Orion R, et al. New insights into the treatment of Glanzmann thrombasthenia. Transf Med Rev. 2016; 30: 92–99.

  • 9

    Salaj P, Brabec P, Penka M, et al. Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry, data from the Czech Republic. Haemophilia 2009; 15: 752–759.

  • 10

    Salaj P, Ovesna P, Penka M, et al. Analyses of recombinant activated factor VII treatments from clinical practice for rapid bleeding and acute pain control in haemophilia patients with inhibitors. Haemophilia 2012, 18: e409–e411.

  • 11

    Santagostino E, Mancuso ME, Rocino A, et al. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb Haemost. 2006; 4: 367–371.

  • 12

    Martinowitz U, Kenet G, Lubetski A, et al. Possible role of recombinant activated factor VII (rFVIIa) in the control of hemorrhage associated with massive trauma. Can J Anaesth. 2002; 49: S15–S20.

  • 13

    MASAC Recommendations concerning products licensed for the treatment of hemophilia and other bleeding disorders. National Hemophilia Foundation, Oct 2013.

  • 14

    Hauser CJ, Boffard K, Dutton R, et al. Results of the CONTROL trial: efficacy and safety of recombinant activated factor VII in the management of refractory traumatic hemorrhage. J Trauma 2010, 69: 489–500.

  • 15

    Ekelund K, Hanke G, Stensballe J, et al. Hemostatic resuscitation in postpartum hemorrhage – a supplement to surgery. Acta Obstet Cynecol Scand. 2015; 94: 680–692.

  • 16

    Anselmi A, Guinet P, Ruggieri VG, et al. Safety of recombinant factor VIIa in patients under extracorporeal membrane oxygenation. Eur J Cardiothorac Surg. 2016; 49: 78–84.

  • 17

    Chapman AJ, Blount AL, Davis AT, et al. Recombinant factor VIIa (NovoSeven RT) use in high risk cardiac surgery. Eur J Cardiothorac Surg. 2011; 40: 1314–1318.

  • 18

    Perel P, Roberts I, Shakur H, et al. Withdrawn: Haemostatic drugs for traumatic brain injury. Cochrane Database Syst Rev. 2015; 13: CD007877.

  • 19

    Udvardy M, Telek B, Mezey G, et al. Successful control of massive coumarol-induced acute upper gastrointestinal bleeding and correction of prothrombin time by recombinant active factor VII (Eptacog-alpha, NovoSeven) in a patient with a prosthetic aortic valve and two malignancies (chronic lymphoid leukaemia and lung cancer). Blood Coagul Fibr. 2004; 15: 265–267.

  • 20

    Grochova M, Kalnasova B, Firment J, et al. Pulmonary administration of activated recombinant factor VII. Bratisl Lek Listy. 2011; 112: 29–33.

  • 21

    Udvardy M, Selmeczi A, Egyed M, et al. Toward optimised intrapulmonary and systhemic hemostatic interventions in diffuse alveolar hemorrhage, a single center experience. Blood 2016; 126: 4686.

  • 22

    Yuan Q, Wu X, Du ZY, et al. Low-dose recombinant factor VIIa for reversing coagulopathy in patients with isolated traumatic brain injury. J Crit Care 2015; 30: 116–120.